TILs as a predictor in nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at how immune cells called TILs (tumor-infiltrating lymphocytes) in your tumor tissue might predict outcomes for nasopharyngeal cancer. It may help doctors better understand your cancer and guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer (a type of head and neck cancer).
- Your cancer is stage II or III when first treated and has not spread to distant parts of the body.
- You are between 18 and 70 years old and are in generally good health (able to carry out daily activities).
- Your blood counts and liver/kidney function are within normal ranges (your doctor will check these).
- You have enough tumor tissue stored from a biopsy to be used for research.
- You are not pregnant, breastfeeding, or unwilling to use birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tissue and blood samples from people already treated for nasopharyngeal carcinoma to find markers that predict how well treatment works and to identify new ways to treat the cancer. It may help doctors personalise care in the future.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This study tests two immunotherapy drugs together for people whose nasopharyngeal cancer has continued to grow after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.